Estimation of Muscle Mass in the Integrated Assessment of Patients on Hemodialysis

Assessment of muscle mass (MM) or its proxies, lean tissue mass (LTM) or fat-free mass (FFM), is an integral part of the diagnosis of protein-energy wasting (PEW) and sarcopenia in patients on hemodialysis (HD). Both sarcopenia and PEW are related to a loss of functionality and also increased morbidity and mortality in this patient population. However, loss of MM is a part of a wider spectrum, including inflammation and fluid overload. As both sarcopenia and PEW are amendable to treatment, estimation of MM regularly is therefore of major clinical relevance. Whereas, computer-assisted tomography (CT) or dual-energy X-ray absorptiometry (DXA) is considered a reference method, it is unsuitable as a method for routine clinical monitoring. In this review, different bedside methods to estimate MM or its proxies in patients on HD will be discussed, with emphasis on biochemical methods, simplified creatinine index (SCI), bioimpedance spectroscopy (BIS), and muscle ultrasound (US). Body composition parameters of all methods are related to the outcome and appear relevant in clinical practice. The US is the only parameter by which muscle dimensions are measured. BIS and SCI are also dependent on either theoretical assumptions or the use of population-specific regression equations. Potential caveats of the methods are that SCI can be influenced by residual renal function, BIS can be influenced by fluid overload, although the latter may be circumvented by the use of a three-compartment model, and that muscle US reflects regional and not whole body MM. In conclusion, both SCI and BIS as well as muscle US are all valuable methods that can be applied for bedside nutritional assessment in patients on HD and appear suitable for routine follow-up. The choice for either method depends on local preferences. However, estimation of MM or its proxies should always be part of a multidimensional assessment of the patient followed by a personalized treatment strategy

Determinants of above-ground carbon stocks and productivity in secondary forests along a 3000-m elevation gradient in the Ecuadorian Andes

Background: Secondary montane forests, covering 30% of forested lands in the Andes, play a crucial role in mitigating the impact of carbon release. However, the mechanisms responsible for carbon sequestration in the above-ground biomass of these forests are not well quantified. Aims: Understanding the determinants of above-ground carbon (AGC) dynamics in secondary forests along a 3000-m elevational gradient in the Andes to assess their mitigation potential. Methods: We assessed how abiotic and biotic conditions and past human disturbances were related to forest structure and composition, AGC stocks and productivity within sixteen 0.36-ha plots established in secondary forest stands of 30–35 years of age. Results: Structural equation models revealed that changes in temperature conditions along the elevation gradient shaped leaf functional composition, which in turn controlled AGC dynamics. Productivity and temperature decreased with increasing elevation and decreased tree community leaf area. Disturbance legacy (Tree mortality) increased with competitive thinning and low soil fertility. Conclusions: We show that temperature drives AGC dynamics by changing the functional trait composition. This highlights the importance of preserving these forests along elevation gradients and implies potentially strong future changes due to global warming.</p

HST/WFC3 Confirmation of the Inside-Out Growth of Massive Galaxies at 0<z<2 and Identification of their Star Forming Progenitors at z~3

We study the structural evolution of massive galaxies by linking progenitors and descendants at a constant cumulative number density of n_c=1.4x10^{-4} Mpc^{-3} to z~3. Structural parameters were measured by fitting Sersic profiles to high resolution CANDELS HST WFC3 J_{125} and H_{160} imaging in the UKIDSS-UDS at 1<z<3 and ACS I_{814} imaging in COSMOS at 0.25<z<1. At a given redshift, we selected the HST band that most closely samples a common rest-frame wavelength so as to minimize systematics from color gradients in galaxies. At fixed n_c, galaxies grow in stellar mass by a factor of ~3 from z~3 to z~0. The size evolution is complex: galaxies appear roughly constant in size from z~3 to z~2 and then grow rapidly to lower redshifts. The evolution in the surface mass density profiles indicates that most of the mass at r<2 kpc was in place by z~2, and that most of the new mass growth occurred at larger radii. This inside-out mass growth is therefore responsible for the larger sizes and higher Sersic indices of the descendants toward low redshift. At z<2, the effective radius evolves with the stellar mass as r_e M^{2.0}, consistent with scenarios that find dissipationless minor mergers to be a key driver of size evolution. The progenitors at z~3 were likely star-forming disks with r_e~2 kpc, based on their low Sersic index of n~1, low median axis ratio of b/a~0.52, and typical location in the star-forming region of the U-V versus V-J diagram. By z~1.5, many of these star-forming disks disappeared, giving rise to compact quiescent galaxies. Toward lower redshifts, these galaxies continued to assemble mass at larger radii and became the local ellipticals that dominate the high mass end of the mass function at the present epoch.Comment: 12 pages, 8 figures in main text + appendix. v2 reflects the version that was accepted to ApJ after addressing the referee repor

Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008

Background: Antiviral susceptibility surveillance in the Netherlands was intensified after the first reports about the emergence of influenza A(H1N1) oseltamivir resistant viruses in Norway in January, 2008. Methods: Within the existing influenza surveillance an additional questionnaire study was performed to retrospectively assess possible risk factors and establish clinical outcome of all patients with influenza virus A(H1N1) positive specimens. To discriminate resistant and sensitive viruses, fifty percent inhibitory concentrations for the neuramidase inhibitors oseltamivir and zanamivir were determined in a neuraminidase inhibition assay. Mutations previously associated with resistance to neuramidase inhibitors and M2 blockers (amantadine and rimantadine) were searched for by nucleotide sequencing of neuraminidase and M2 genes respectively. Results: Among 171 patients infected with A(H1N1) viruses an overall prevalence of oseltamivi resistance of 27% (95% CI: 20-34%) was found. None of influenza A(H1N1) oseltamivir resistant viruses tested was resistant against amantadine or zanamivir. Patient characteristics, underlying conditions, influenza vaccination, symptoms, complications, and exposure to oseltamivir and other antivirals did not differ significantly between patients infected with resistant and sensitive A(H1N1) viruses. Conclusion: In 2007/2008 a large proportion of influenza A(H1N1) viruses resistant to oseltamivir was detected. There were no clinical differences between patients infected with resistant and sensitive A(H1N1) viruses. Continuous monitoring of the antiviral drug sensitivity profile of influenza viruses is justified, preferably using the existing sentinel surveillance, however, complemented with data from the more severe end of the clinical spectrum. In order to act timely on emergencies of public health importance we suggest setting up a surveillance system that can guarantee rapid access to the latter. (aut. ref.

Should a fistula first policy be revisited in elderly haemodialysis patients?

Life-sustaining haemodialysis requires a durable vascular access (VA) to the circulatory system. The ideal permanent VA must provide longevity for use with minimal complication rate and supply sufficient blood flow to deliver the prescribed dialysis dosage. Arteriovenous fistulas (AVFs) have been endorsed by many professional societies as the VA of choice. However, the high prevalence of comorbidities, particularly diabetes mellitus, peripheral vascular disease and arterial hypertension in elderly people, usually make VA creation more difficult in the elderly. Many of these patients may have an insufficient vasculature for AVF maturation. Furthermore, many AVFs created prior to the initiation of haemodialysis may never be used due to the competing risk of death before dialysis is required. As such, an arteriovenous graft and, in some cases, a central venous catheter, become a valid alternative form of VA. Consequently, there are multiple decision points that require careful reflection before an AVF is placed in the elderly. The traditional metrics of access patency, failure and infection are now being seen in a broader context that includes procedure burden, quality of life, patient preferences, morbidity, mortality and cost. This article of the European Dialysis (EUDIAL) Working Group of ERA-EDTA critically reviews the current evidence on VA in elderly haemodialysis patients and concludes that a pragmatic patient-centred approach is mandatory, thus considering the possibility that the AVF first approach should not be an absolute

Het Rijksvaccinatieprogramma in Nederland. Ontwikkelingen in 2006

In 2006 several changes were made in the Dutch National Immunisation Programme (NIP): Hepatitis B vaccination at birth was added for children born to mothers positive for hepatitis B surface antigen; a new vaccine for diphtheria, tetanus, pertussis (a-cellular), poliomyelitis and Haemophilus influenzae (DTaP-IPV/Hib) was introduced; vaccination against pneumococcal disease was added at two, three, four and eleven months; risk groups for hepatitis B receive a combined vaccine for DTaP-IPV/Hib and HBV at the same ages; DT-IPV and aP at the age of four years were combined in one vaccine; and new MMR vaccines were introduced. As new information became available in 2006, the desirability to introduce vaccinations in the NIP for the following diseases could be (re)considered: hepatitis B (universal vaccination), rotavirus, varicella and human papillomavirus. For respiratory syncytial virus and meningococcal serogroup B disease no candidate vaccines are available yet. Extension of the programme with available vaccines for hepatitis A, influenza and tuberculosis is not (yet) recommended. The NIP in the Netherlands is effective and safe. However, continued monitoring of the effectiveness and safety of the NIP is important as changes are made regularly. Maintaining high vaccine uptake is vital to prevent (re)emergence of diseases. Furthermore, the programme should be regularly reviewed as new vaccines become available.In 2006 traden verschillende veranderingen op in het Rijksvaccinatieprogramma (RVP) in Nederland: kinderen die geboren worden uit moeders die chronisch geinfecteerd zijn met hepatitis B krijgen vlak na de geboorte een hepatitis B vaccinatie; er is een ander vaccin geintroduceerd voor difterie, kinkhoest (a-cellulair), tetanus, poliomyelitis en Haemophilus influenzae (DaKTP/Hib); vaccinatie tegen pneumokokken is toegevoegd op de leeftijd van 2, drie, vier en elf maanden; risicogroepen voor hepatitis B krijgen op diezelfde leeftijden een combinatievaccin voor DaKTP/Hib en hepatitis B; DTP en aK zijn gecombineerd in een vaccin op vierjarige leeftijd; en er zijn nieuwe BMR vaccins geintroduceerd. Op basis van informatie die in 2006 beschikbaar is gekomen wordt geadviseerd de introductie van vaccinaties voor de volgende ziekten te overwegen: hepatitis B (universele vaccinatie), rotavirus, waterpokken en humaan papillomavirus. Voor respiratoir syncytieel virus en meningokokken B zijn nog geen kandidaatvaccins beschikbaar en uitbreiding van het RVP met beschikbare vaccins voor hepatitis A, influenza en tuberculose wordt nog niet aanbevolen. Het RVP is effectief en veilig, maar voortdurende bewaking hiervan is groot belang, omdat er regelmatig veranderingen optreden. Handhaven van de hoge vaccinatiegraad is essentieel om terugkeer van ziekten te voorkomen. Verder moet regelmatig bekeken worden of het RVP aangepast moet worden aangezien er steeds nieuwe vaccins beschikbaar komen

THE VLT LEGA-C spectroscopic survey:the physics of galaxies at a lookback time of 7 Gyr

The Large Early Galaxy Census (LEGA-C) is a Public Spectroscopic Survey of ~3200 K-band selected galaxies at redshifts z = 0.6 − 1.0 with stellar masses ${M}_{*}\gt {10}^{10}\quad {M}_{\odot }$, conducted with VIMOS on ESO's Very Large Telescope. The survey is embedded in the COSMOS field (R.A. = 10h00; $\mathrm{decl}.\;=\;+2\;\mathrm{deg}$). The 20 hr long integrations produce high-signal-to-noise ratio continuum spectra that reveal ages, metallicities and velocity dispersions of the stellar populations. LEGA-C's unique combination of sample size and depth will enable us for the first time to map the stellar content at large lookback time, across galaxies of different types and star formation activity. Observations started in 2014 December and are planned to be completed by mid 2018, with early data releases of the spectra and value-added products. In this paper we present the science case, the observing strategy, an overview of the data reduction process and data products, and a first look at the relationship between galaxy structure and spectral properties, as it existed 7 Gyr ago